MarginsXMarginsX
Home › Markets › Health Care › MESO

Mesoblast Limited (MESO)

MESO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$12.45
-6.18% on the day
Market cap
$1.6B
Small cap
Revenue · 2026
$120.3M
+599.2% on 2025
Net income · 2026
-$57.5M
-47.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1345099/000134509926000081/0001345099-26-000081-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerMESO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryAustralia
IPO year2015
SEC CIK0001345099
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inAustralia

Financials · 2026

LineValue
Revenue$120.3M
Net income-$57.5M
Operating incomeNot in SEC XBRL data
Net margin-47.8%
Operating marginOperating income not reported
Revenue growth+599.2%
Cash$102.9M
Total assets$773.1M
P/E (computed)Net income was not positive
P/S (computed)13.5×

Warning signs

Cash runway
28.2 months
$102.9M cash at June 30, 2026
Share count, 1 year
+1.3%
2025-06-30 to 2026-06-30 · +218.6% over 3 years
Going-concern doubt
No
20-F filed August 27, 2026
Insider net buying, 12 months
$19.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-08-27
Cash and burn$102.9M cash; operating cash flow -$11.0M a quarter.Report 2026-06-30
Shares outstanding129,686,278 (2026-06-30); 127,996,719 a year earlier; 81,420,483 three years earlier. 3y figure adjusted for split (1-for-2 overall).Cover page 2026-06-30
Reverse splits, 3 years1; latest 1-for-2 on 2024-01-10Source 2024-01-10
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2025-12-31
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers, Melbourne, AustraliaPCAOB Form AP 2026-09-14
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $19.6M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-06-30
$120.3M-$57.5M-$43.8M$102.9M$119.2M$120.3M20-F 2026-08-27
FY 2025
2025-06-30
$17.2M-$102.1M-$50.0M$161.6M$121.9M$17.2M20-F 2025-08-29
FY 2024
2024-06-30
$5.9M-$88.0M-$48.5M$63.0M$114.3M$5.9M20-F 2025-08-29
FY 2023
2023-06-30
$7.5M-$81.9M-$63.3M$71.3M$108.8M$7.5M20-F 2025-08-29
FY 2022
2022-06-30
$10.2M-$91.3M-$65.8M$60.4M$101.7M$10.2M20-F 2024-08-29
FY 2021
2021-06-30
$7.4M-$98.8M-$100.7M$136.9M$147.4M$7.4M20-F 2023-08-31
FY 2020
2020-06-30
$32.2M-$77.9M-$50.4M$129.3M$89.5M$32.2M20-F 2022-08-31
FY 2019
2019-06-30
$16.7M-$89.8M-$57.8M$50.4M$81.3M$16.7M20-F 2021-08-31

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B32026-01-14
Latest annual report20-F2026-08-27
Latest quarterly / interim6-K2026-11-16

Source: SEC EDGAR submissions feed, 600 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.0%
1 month-4.5%
3 months-19.5%
Year to date-26.4%
1 year-11.1%
From 52-week high-36.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
VIRVir Biotechnology Inc.$9.58-3.82%$1.6B
ALVOAlvotech$4.41+5.13%$1.7B
WWBWindward Bio Group AG Common Shares$30.04+5.40%$1.7B
IMCRImmunocore Holdings plc$28.88-3.54%$1.5B
LYCALycia Therapeutics Inc.$28.61-8.30%$1.5B
RXRXRecursion Pharmaceuticals Inc.$2.90-8.79%$1.8B
COAGHemab Therapeutics Holdings Inc.$39.05-4.42%$1.8B
MAZEMaze Therapeutics Inc.$33.90-1.25%$1.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier